HIKMA Pharmaceuticals PLC — Remuneration Information 2017

Apr 13, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4388C

Hikma Pharmaceuticals Plc

13 April 2017

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 13 April 2017: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards and nil cost options under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the EIP were made on 13 April 2017 at a price of 1,740 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2016, in accordance with the EIP rules) as follows:

Notification and public disclosure of transactions by persons discharging managerial responsibilities

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Majda Labadi
2	Reason for the notification
a)	Position/status	Corporate Vice President for Human Resources and Head of Operations, MENA
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £17.40 Volume(s): 17,825
d)	Aggregated information	N/A
e)	Date of the transaction	13 April 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Majda Labadi
2	Reason for the notification
a)	Position/status	Corporate Vice President for Human Resources and Head of Operations, MENA
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £17.40 Volume(s): 16,146
d)	Aggregated information	N/A
e)	Date of the transaction	13 April 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	Vice President, Corporate Strategy and Investor Relations
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a nil cost option to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years.
c)	Price(s) and volume(s)	Price(s): £17.40 Volume(s): 14,031
d)	Aggregated information	N/A
e)	Date of the transaction	13 April 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	Vice President, Corporate Strategy and Investor Relations
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a nil cost option to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years.
c)	Price(s) and volume(s)	Price(s): £17.40 Volume(s): 13,477
d)	Aggregated information	N/A
e)	Date of the transaction	13 April 2017
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHGRGDSBSBBGRX